|
Total number of patients
|
193
|
662
|
|
Median age, years (range)
|
75 (71–88)
|
55 (16–70)
|
|
Male/female, n (%)
|
112 (58)/81 (42)
|
348 (53)/314 (47)
|
|
ECOG performance status, n (%)
| | |
|
0
|
105 (54)
|
458 (69)
|
|
1
|
83 (43)
|
184 (28)
|
|
2
|
5 (3)
|
20 (3)
|
|
Time from diagnosis, months (range)
|
35 (3–280)
|
40 (3–280)
|
|
LDH level, n/n (%)a
| | |
|
< 1.10 ULN
|
108/175 (62)
|
336/545 (62)
|
|
≥ 1.10 ULN
|
67/175 (38)
|
209/545 (38)
|
|
Number of previous therapies, n (%)
| | |
|
1
|
128 (66)
|
369 (56)
|
|
2
|
41 (21)
|
192 (29)
|
|
≥ 3
|
24 (13)
|
101 (15)
|
|
Previous therapy, n (%)
| | |
|
Dacarbazine
|
113 (59)
|
377 (57)
|
|
Fotemustine
|
54 (28)
|
268 (41)
|
|
Platinum-based chemotherapy
|
42 (22)
|
274 (41)
|
|
Temozolomide
|
40 (21)
|
149 (23)
|
|
Interferon
|
22 (11)
|
172 (26)
|
|
BRAF inhibitor
|
8 (4)
|
51 (8)
|
|
Patients with brain metastases, n (%)
|
17 (9)
|
129 (20)
|
|
Patients with liver metastases, n (%)
|
75 (39)
|
264 (40)
|
